RE:RE:RE:RE:ONCY bispecific in development (pelareorep x CD3)Building on my previous post:
If the big pharma world collectively accepts the statement of Dr. von Monfoort, our subjective expected value as a company, in terms of medium term NPV, should perhaps be double what people thought previously, IMHO.